Evidence map›Paper›PMID 35738852›Full record

Trial reportJACC. Clinical electrophysiology2022

Reduction in Ventricular Tachyarrhythmia Burden in Patients Enrolled in the RAID Trial.

Arwa Younis, Ilan Goldenberg, Shamroz Farooq, Hagai Yavin, James Daubert, Merritt Raitt, Alexander Mazur, David T Huang, Brent L Mitchell, Mayer R Rashtian and 7 more

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in JACC. Clinical electrophysiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01215253 (Late Sodium Current Blockade in High-Risk ICD Patients), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01215253 phase3completednot on this map

Late Sodium Current Blockade in High-Risk ICD Patients

TypeinterventionalSponsorUniversity of RochesterRan2011 to 2017Enrolled1,012ConditionsIschemic Cardiomyopathy, Nonischemic Cardiomyopathy, Heart FailureArmsRanolazine
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 10 institutions in 2 countries.

Arwa YounisCardiology Division, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA; Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA. Electronic address: or.younis@gmail.com.
Ilan GoldenbergCardiology Division, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.
Shamroz FarooqCardiology Division, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.
Hagai YavinHeart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.
James DaubertDepartment of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Merritt RaittDivision of Cardiology, VA Portland Health Care System and Knight Cardiovascular Institute, Oregon Health and Sciences University, Portland VA Medical Center, Portland, Oregon, USA.
Alexander MazurDivision of Cardiovascular Medicine, University of Iowa, Iowa City, Iowa, USA.
David T HuangCardiology Division, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.
Brent L MitchellDivision of Cardiology, University of Calgary, Calgary, Canada.
Mayer R RashtianDepartment of Cardiology, Huntington Memorial Hospital, Pasadena, California, USA.
Stephen WintersDepartment of Cardiovascular Medicine, Morristown Medical Center, Morristown, New Jersey, USA.
Margot VlokaCardiology Division, Saint Alphonsus Health System, Boise, Idaho, USA.
Mehmet AktasCardiology Division, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.
Matthew A BernabeiLancaster Heart and Vascular Institute, Lancaster, Pennsylvania, USA.
Christopher A BeckDepartment of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, New York, USA.
Scott McNittCardiology Division, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.
Wojciech ZarebaCardiology Division, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA. Electronic address: wojciech_zareba@urmc.rochester.edu.
University of Rochester Medical Center · USCleveland Clinic · USDuke Medical Center · USHuntington Hospital · USLancaster General Hospital · USMorristown Medical Center · USPortland VA Medical Center · USSaint Alphonsus Health System · USUniversity of Calgary · CAUniversity of Iowa · US

Funding

Late Sodium Current Blockade in High-Risk ICD Patients - CCC - Lead ApplicationU01HL096607 · NHLBI · UNIVERSITY OF ROCHESTER · PI ZAREBA, WOJCIECH · 2010 to 2015
$5.9M
Late Sodium Current Blockade in High-Risk ICD Patients - DCCU01HL096610 · NHLBI · UNIVERSITY OF ROCHESTER · PI ZAREBA, WOJCIECH · 2010 to 2015
$3.4M
NHLBI NIH HHS U01 HL096607NHLBI NIH HHS U01 HL096610
6 · The paper itself

Abstract

backgroundThe RAID (Ranolazine Implantable Cardioverter-Defibrillator) randomized placebo-controlled trial showed that ranolazine treatment was associated with reduction in recurrent ventricular tachycardia (VT) requiring appropriate implantable cardioverter-defibrillator (ICD) therapy.

objectivesThis study aimed to identify groups of patients in whom ranolazine treatment would result in the highest reduction of ventricular tachyarrhythmia (VTA) burden.

methodsAndersen-Gill analyses were performed to identify variables associated with risk for VTA burden among 1,012 patients enrolled in RAID. The primary endpoint was VTA burden defined as VTA episodes requiring appropriate treatment.

resultsMultivariate analysis identified 7 factors associated with increased VTA burden: history of VTA, age ≥65 years, New York Heart Association functional class ≥III, QRS complex (≥130 ms), low ejection fraction (<30%), atrial fibrillation (AF), and concomitant antiarrhythmic drug (AAD) therapy. The effect of ranolazine on VTA burden was seen among patients without concomitant AAD therapy (HR [HR]: 0.68; 95% CI: 0.55-0.84; P < 0.001), whereas no effect was seen among those who are concomitantly treated with other AADs (HR: 1.33; 95% CI: 0.90-1.96; P = 0.16); P = 0.003 for interaction. In patients with cardiac resynchronization therapy (CRT) ICDs, ranolazine treatment was associated with a 36% risk reduction for VTA recurrence (HR: 0.64; 95% CI: 0.47-0.86; P < 0.001), whereas among patients with ICDs without CRT no significant effect was noted (HR: 0.94; 95% CI: 0.74-1.18; P = 0.57); P = 0.047 for interaction.

conclusionsIn patients with high risk for VTA, ranolazine is effective in reducing VTA burden, with significantly greater effect in CRT-treated patients, those without AF, and those not treated with concomitant AADs. In patients already on AADs or those with AF, the addition of ranolazine did not affect VTA burden. (Ranolazine Implantable Cardioverter-Defibrillator Trial [RAID]; NCT01215253).

Indexed as

Defibrillators, ImplantableRanolazineTachycardia, VentricularAgedHumansRanolazinearrhythmiacardioverter-defibrillatorICDranolazineventricular tachycardia

Identifiers

PMID35738852
PMCPMC9473303
OpenAlexW4283466180

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.